A NEW DIMENSION TO OPEN WOUND TREATMENT
STRIVING TO MAKE THE WORLD A HEALTHIER PLACE
Pathelen® (European Class 1 Certified Medical Device), a pioneering, side effect free treatment for open wound infections like MRSA, MDR, ESBL, and antibiotic-resistant bacteria (Superbugs), advancing existing capabilities of wound-care in public, private and military hospitals.
UniPharma is a newly formed company licensed to market, and supply Pathelen in Ghana, Nigeria, projectively the wider African continent and Qatar.
We are focused on solving the issue of anti-microbial resistance in open wounds, preventing suffering, treating patients rapidly, effectively and cheaply and saving millions of lives worldwide.
United Nations and WHO warn that antimicrobial resistance has become one of the biggest threats to global health.
Pathelen, is a far more effective replacement for all antimicrobial wound treatment devices that bacteria cannot develop resistance to. It can solve this problem!
Pathelen is a patented, European Medicine Agency C1 approved medical device and incredibly versatile, working internally and externally on infections ranging from MRSA to infectious diarrhoea.
Pathelen Health Care AG has developed Pathelen over several years and done over 1000 successful case studies, culminating in UniPharma running a successful case studies in Ghana since March 2019.
UniPharma have subsidiaries setup and trademarks registered in Ghana and Nigeria and have been awarded a temporary NAFDAC licence in Nigeria.
Pathelen is about to be placed on the ‘Essential Medicine’ list in Ghana and UniPharma have trials underway and orders from government institutions in Ghana and Nigeria.
Pathelen is produced by Pathelen Health Care AG who signed an exclusivity agreement with UniPharma in 2018 for the marketing and distribution of the products in selected African countries and Qatar.
UniPharma are in the process of raising an investment round to scale the company rapidly.
ABOUT PATHELEN WOUNPOWDER
Supporting the World to solve the Anti-Microbial Resistance Crisis
Pathelen® is a medical device, specifically designed and developed for the treatment of multi-resistant bacteria (such as MRSA) in open wounds. Vitally, bacteria are unable to develop resistance to it, in contrast to all antibiotics designed to perform a similar function.
Pathelen® eliminates most external bacterial wound infections within 5-10 days, with use cases such as preparing for a wound closure surgery or enhancing the growth of granulating tissue on the treated wound.
It has a wide range of antimicrobial uses, highly effective in combating gram-positive and gram-negative aerobic and anaerobic micro-organisms (clostridial and non-clostridial in composition with aerobic and facultative anaerobic).
Germs which can be typically treated with Pathelen® are:
Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), Enterobacteria i.e. – Escherichia coli – Klebsiella pneumoniae – Klebsiella oxytoca, Proteus mirabilis, Non-fermenting organisms i.e. Pseudomonas aeruginosa – Acinetobacter baumannii – Pseudomonas
Key Pharmaceutical Properties
Clinical practice shows that the current, individual use of other antimicrobial agents in the treatment of purulo-inflammatory diseases and purulent wounds, does not always lead to the desired result. Additionally, misuse of antibiotics has contributed to the emergence of resistant (hospital) strains of pathogenic micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and become a serious challenge for modern medicine.
Pathelen® can solve this problem, utilising new compositions based on highly dispersed silicas and polymethylsiloxane which have enhanced absorptive, anti-inflammatory and wound-healing abilities for the treatment of a wide range of diseases caused by pathogenic micro-organisms, in particular, purulent wounds.
The intensity of the regeneration process and healing of infected ulcers and wounds depends largely on the speed with which they are cleared of pus and necrotic tissues. Applique sorption, a method of wound healing in which an absorbent in powder form is applied to the wound as a dressing, greatly accelerates this process. This absorption detoxification restores the integrity of the skin and mucous membranes by the removal of microbial cells, bacterial toxins and toxic metabolites of wound fluid and wound cavities in direct contact with the surface of Pathelen®.
Another important therapeutic factor in the first phase of wound healing is dehydration, i.e. absorption of fluid from the wound cavity and perifocal tissues. Hydrophilic highly dispersed silica (HDS) can be used in the first phase of wound healing. Its detoxifying action is due to the absorption of pathogenic protein substances (up to 800 mg/g), including microbial enzymes, exo- and endotoxins (Lipopolysaccharides) and micro-organisms.
Innovative & Unique Treatment
Pathelen® is a pioneering new treatment for a wide range of wounds in soft tissues with aerobic and anaerobic infections, for previously incurable wounds and for common chronic wound diseases including:
Chronic pressure ulcers
Venous leg ulcers
Fungating, cancerous or malignant lesions and wounds with necrotic tissue.
Pathelen® can prevent bacterial infections in post-op wound treatment and has haemostatic action (a process which causes bleeding to stop).
Some strains of MRSA are resistant to all kinds of antibiotics. Pathelen®, due to its affinity to proteins, heals uniquely by agglutinating (clumping together) microorganisms which have protein molecules on the surface.
Through its revolutionary strategy, a local physical absorption treatment of wound bacteria is used instead of the traditional approach of a systemic antibiotic treatment. Pathelen® can even successfully treat ongoing, irreparable wound infections, which are "protected" by a biofilm, or wounds which are contaminated with antibiotic resistant MRSA and extended spectrum beta lactamases (ESBL) producing bacteria like E. coli and Klebsiella.
The most typical problems of patients with these wounds are:
Rapid destruction of tissue
Slow detersion of a wound
Increase of infectious and inflammatory process (SIRS, sepsis)
The unique effect of Pathelen is achieved through various simultaneous mechanisms:
Elimination of the biofilm
Sorption of necrotic tissues
Sorption of pus and toxins (including large amounts of problematic lipopolysaccharides)
Preparation of a physiological wound environment with granulating tissue
Why is Pathelen so Effective?
Rapidly removes toxins from any wound and heals it
Bacteria can’t develop resistance
Blocks corrosive properties of saliva and lymph
Very high sorption and does not penetrate the blood circle
Removes bacteria and prevents it from re-entering the wound
Efficiently eliminates the multi-resistant bacteria flora
Destroys micro-organism optimal living conditions
Inhibits surface and intracavitary bleeding
Reduces risk of sepsis and considerably reduces infection
Decreases exotoxins production
Can be used with other medicines and has no known side effects
Easy to store and use requires minimal training
Pathelen Health Care AG
PHC AG is a highly funded organisation founded in 2008 by Andreas Tausch, a biochemist and philanthropist.
He conceived the unique and ground-breaking Pathelen formula, which has changed the way we approach wound treatment. Subsequently, Pathelen has been refined, tested and patented to its present highly marketable status and been the subject of thousands of successful case studies over a number of years. Although Pathelen has been the initial focus of the company, other equally effective products are pending release.
Unitas have a strong personal and contractual relationship with PHC AG and are heavily aligned in making Pathelen available for a highly successful treatment in many forms.
THE UNIPHARMA TEAM
Get to Know Us
Chief Branding Officer
An international, multilingual, entrepreneur having worked across Europe for over 20 years on high value & highly complex and sophisticated projects, Daphne Diluce has carved a successful path in global branding, film production, creating wonderful work empowering many companies. Whilst living in Germany Daphne Diluce excelled in working in film, creating Marketing Ads & Films for a Global market working on many prestigious projects closely and alongside brands like Jägermeister, Poly lady, Coppenrath & Wises and many more. Transitioning into the world of Design she became a highly skilled Interior Designer & Lighting expert winning large commercial projects across Europe creating, purchasing, project managing and completing large and complex projects all in time, and on budget. Complementing these great achievements, Daphne Diluce also had an Interior Design Store & soft furniture manufacture acclaimed for being in the best top-ten stores in Dusseldorf and is the founder/designer of ‘fusion io’ an automated, digital & AI marketing platform that carries powerful brand elements out into the global market.
Chief Marketing Officer
A successfully global entrepreneur, Stephen Gillen build his first multi-million-pound company with his family over a three-year period in the construction industry 10 years ago. He next went into different diverse industries having an IT & Media company producing documentaries on the world’s most successful empires and dynasties which gained global traction being viewed in over 130 countries. A next successful innovation was in founding Shooting Stars Events a pioneering global company that solved many important pain-points in the Film, Music, PR & Media Industry. Since then he has gone on to gain a high profile in the broadcast media and TV, be a multi-award winning entrepreneur, writer, international public speaker, earlier this year being nominated by the UK Peace Ambassador for the prestigious 2020 Sunhak Peace Prize for distinguished humanitarian work.
CEO / Co-Founder
A serial entrepreneur, having founded businesses over 20 years in executive search, consultancy, FX and distribution. Thomas has worked with some of the most successful global businesses which include Hilton Hotels, Laduree, Conrad Hotels and 5 Guys. This experience perfectly positions him as CEO of UniPharma.
CCO & CDO / Co-Founder
As Chief Communications & Development Officer with an eminent profile in Ghana, Eric helps investors identify opportunities in Africa. His network spans high net worth individuals through to the top reaches of the Africa Elite and prominent figures on the Arabian peninsular. He set up Dumont Noir, the successful luxury concierge and asset intermediary, honing management, marketing and communication skills and developing his world class network.
Jay has attained director level seniority within highly reputable organisations, demonstrating exceptional commercial awareness and business acumen. He possesses a dedication to training and development, strong sales and negotiation skills, and the ability to create sophisticated plans for growth and loss prevention. Jay has held senior positions at DHL where he worked his way up to Country Manager level. He will head the full Africa launch of Pathelen.
COO / Co-Founder
An experienced senior leader across the sales, hospitality and distribution sectors, Paolo is an operations expert. He has been working successfully alongside Thomas in operations and finance for the last 12 years. UniPharma is the latest exciting venture of this highly credible partnership.
FD UniPharma / MD Unitas Group US
Jeyson attended Saint Peter’s University in New Jersey on a football scholarship attaining a degree in International Business and Trade. He went on to lead the global credit and collections team at Panasonic Electronics US. He has since held Finance executive roles within global conglomerates such as Morgan Stanley, Pearson Education, American Express, and NBC Universal. He currently holds the designation of Certified International Credit Professional (CICP) awarded in December 2011. Jeyson has taken on the US territory and has already developed our Unitas services into the US.
Gilles is the founder of GM avocats. He is qualified as Avocat au Barreau de Paris (1998) and Solicitor of England & Wales (2006) and attended Paris Sorbonne and Harvard Law School. Since 1995 Gilles has developed a comprehensive expertise in international transaction deals contracts, corporate and M&A, litigation, and in the role of general counsel to international clients. He teaches Franchise and European Distribution law as adjunct professor for Master students at the Paris Nanterre University. Since 2015, at the invitation of the US Government, Gilles has assisted the Tunisian Government in the modernisation of its legal environment in relation to franchising, the ultimate goal being to enhance international trade.
DR. ISMAIL OYEBAMIRE
Consultant Medical Doctor
Dr Ismail is a highly qualified physician specialising in infectious diseases. He is originally from Nigeria and is currently a resident doctor at Regional Clinical Infectious Hospital, Kharkiv, Ukraine, where he has had his research published. He brings an invaluable medical lens to growth of Unitas.
He is a consultant and advisor and has been on the ground with the team to help educate Ghanaian and Nigerian doctors on Pathelen, guide their device implementation and successfully oversee multiple case studies and trials.
He has become an expert in the capabilities and application of Pathelen and will help shape progressive implementations for the medical device. He will also spearhead all clinical trials and training for African countries and help develop a scalable training and growth strategy for the UniPharma Medical Team.
WANT TO FIND OUT MORE ABOUT OUR INVESTMENT ROUND?
Leave your name and email and we'll send you more info.
JUST WANT TO CHAT?
Leave your name and email and let us know what you'd like to chat about.
Chief Logistics Officer / MD Nigeria
Paul runs a successful distribution business in Nigeria with Woaw! Logistics, which distributes 50% of the medical and pharmaceutical products across Nigeria for WCW. Through Woaw! he has built a very extensive network and is connected to the top tiers of government and the military in Nigeria.
TERMS & CONDITIONS
Unipharma Holding Ltd uses reasonable care compiling and presenting the information found on this web site. All other information is supplied for information only and you should seek further guidance and make independent enquiries before relying upon it. The information included in this web site has been compiled from a variety of sources and is subject to change without notice.
UniPharma Holding Ltd makes no representation or warranty whatsoever regarding the completeness, accuracy, currency, adequacy, suitability or operation of this web site, or of the information it contains, nor that the information has in any way been verified by Unitas Group.
UniPharma Holding Ltd makes no representation or warranty as to the final terms and duration of any appointment obtained through this web site. To the extent permitted by law, UniPharma Holding Ltd excludes all warranties implied by operation of law. If an implied warranty cannot be excluded, the liability of UniPharma Holding Ltd shall be limited to (at its option) the resupply of services or the cost of having the service resupplied by a third party.
By accessing this website, you assume the risk that the information on this web site may be incomplete, inaccurate, out of date or may not meet your requirements, and agree to be bound by these terms.
To the extent permitted by law, UniPharma Holding Ltd does not warrant that data available for downloading from this web site will be free of worms, viruses, Trojan horses or any other computer code that may manifest any destructive property.
UniPharma Holding Ltd is a company registered in England, Ghana and Nigeria.
Its registered offices are
England: UniPharma Holding Ltd. SVS House, Oliver Grove, London, SE25 6EJ and the company registration number is 11619738. VAT No. 308 4751 02
Ghana: Unitas Pharma Ghana Ltd. 9 NTHC Estates, East Legon, East Legon Road, Accra and the company registration number is CS330352018 VAT pending
Nigeria: Unitas Pharma Nigeria Ltd. 73 Ogunusi Street, Omele Estate, Ikeja, Lagos and the company registration number is and the company registration number is RC 1535689 VAT No. 21131545-0001
Protecting your privacy is our first priority: the nature of our work gives us a particular responsibility to maintain candidate and client confidentiality.
We do not collect any sensitive information about you on our website.
We use IP addresses to analyse trends, administer the site, track users’ movement and gather broad demographic information for aggregate use. IP addresses are not linked to your personally identifiable information.
In order for us to make your use of the site easier, we use something called a “cookie”. A cookie is a collection of information sent by the UniPharma Holding Ltd web server to your computer. This information is stored in such a way that our web server can access it the next time you visit Unitas Group. It is possible to look at the information stored in the cookie but only the web server can understand the contents.
Should you wish to disable the storing of cookies on your computer, you can do so by following the help guide supplied with your browser. If you do not want to do this, you can also set up your browser to inform you when cookies are set. If you have any questions or concerns about any aspect of your privacy on the UniPharma Holding Ltd website, please send an e-mail to
This website contains links to other sites. Please be aware that UniPharma Holding Ltd is not responsible for the privacy practices of such other sites. This privacy statement applies only to information collected by our web site.
Change of policy
We reserve the right to update and change our Privacy Statement. If we materially change our practices in handling personally identifiable information, we will post this on our website at least 30 days before implementation. If you are not happy with any of the changes, contact us using the information below, and we will stop processing your information.
UniPharma Holding Ltd will be known as the “Controller” of the personal data you provide to us. We only collect personal data including: names, addresses, email, phone numbers, online identifiers and employment history*.
Why we need your data
We process personal information on the lawful basis of legitimate interest when performing services.
We process personal information on the lawful basis of contracts when conducting such services, including:
• Pharmaceutical distribution
We will not collect any personal data from you we do not need to provide and oversee this service to you. Whenever we process data for these purposes, we will ensure that we always keep your personal data rights in high regard and take account of these rights. You have the right to object to this processing if you wish, and if you wish to do so please click here to manage your preferences. Please bear in mind that if you object this may affect our ability to carry out the above tasks for your benefit.
What we do with your data
All the personal data we process is processed by our staff in the UK. For the purposes of IT hosting and maintenance this information is located on servers within the European Union. Where appropriate, we process personal data via the third-party software 'Smarteheet'.
How long we keep your data
We are required under UK law to keep your basic personal data (name, address, contact details) for a minimum of 6 years after which time it will be destroyed. We will not use your data for marketing purposes.
What are your rights?
If at any point you believe the information, we process on you is incorrect you can request to see this information (ACCESS) and have it corrected (RECTIFICATION) or deleted (FORGOTTEN). If you wish to raise a complaint on how we have handled your personal data, you can contact us to have the matter investigated.
If you have any questions or queries, please contact us at
All information and images incorporated within this website are © UniPharma 2019.
Trademark and Patent
Pathelen® Woundpowder is a trademarked and Patented medical device owned by Pathelen Health Care AG
Class 1 Registration No CH-201805-0002